<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150852</url>
  </required_header>
  <id_info>
    <org_study_id>04-012 (med 04-008)</org_study_id>
    <nct_id>NCT00150852</nct_id>
  </id_info>
  <brief_title>Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.</brief_title>
  <official_title>Vancomycin for Prophylaxis of PEG-Related Wound Infection in MRSA-Positive Patients: a Double-Blind, Randomized, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether vancomycin with cefazoline is superior to&#xD;
      vancomycin with placebo in preventing gastrostomy-related wound infection in carriers of&#xD;
      methicillin-resistant staphylococcus aureus (MRSA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous endoscopic gastrostomy (PEG) provides an enteral route for long-term nutrition&#xD;
      in patients unable to swallow. Peristomal wound infection occurs in 5 - 30 % of patients.&#xD;
      Systematic antibiotic prophylaxis by cephalosporins or ampicillin/clavulanic acid has been&#xD;
      shown to prevent this complication efficiently.&#xD;
&#xD;
      MRSA-positive patients have been suggested to be at higher risk of PEG-related wound&#xD;
      infection due to MRSA. However, recommendations about vancomycin-prophylaxis before surgical&#xD;
      procedures have not been extended to PEG insertion. This might be due to the fact that the&#xD;
      exact route of contamination is unknown. It is assumed that contamination occurs when&#xD;
      gastrostomy tubes are passed through the oropharynx. However, oropharyngeal carriage appears&#xD;
      less frequent than nasopharyngeal or cutaneous carriage. Furthermore, patients who receive&#xD;
      PEG are particularly vulnerable to vancomycin toxicity because of older age and multiple&#xD;
      comorbidities.&#xD;
&#xD;
      The aim of this study is to compare the rate of infectious complications after PEG insertion&#xD;
      in patients colonized with MRSA who received either standard intravenous antibiotic&#xD;
      prophylaxis associated with vancomycin or standard prophylaxis with placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of PEG-site infection at 3, 7, 14, 21 and 28 days post intervention as assessed by a clinical score (Jain score) and swab culture</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional costs and nursing charges (Programme de Recherche en Nursing (PRN) scoring system)</measure>
  </secondary_outcome>
  <enrollment>96</enrollment>
  <condition>Wound Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PEG insertion in a patient with a swab positive for MRSA during the 4 weeks preceding&#xD;
             PEG insertion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  No informed consent obtained either from the patient or from his legal representative&#xD;
&#xD;
          -  Contraindication to the administration of cefazolin or of vancomycin&#xD;
&#xD;
          -  Systemic administration of antibiotics effective against MRSA during the week prior to&#xD;
             the procedure&#xD;
&#xD;
          -  Technique of PEG insertion different from the standard pull technique proposed by the&#xD;
             physician in charge and the gastroenterologist&#xD;
&#xD;
          -  Patients requiring antibiotic prophylaxis of endocarditis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Vonlaufen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology, University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Vonlaufen, MD</last_name>
    <phone>+41 22 372 93 40</phone>
    <email>Alain.Vonlaufen@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe De Saussure, MD</last_name>
    <phone>+ 41 22 372 93 40</phone>
    <email>Philippe.deSaussure@hcuge.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU)</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agn√®s Plages</last_name>
      <phone>+ 33 476 76 55 97</phone>
      <email>APlages@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Roblin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gian Dorta</last_name>
      <phone>+ 41 21 314 11 11</phone>
      <email>Gian.Dorta@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Gian Dorta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology, University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Vonlaufen, MD</last_name>
      <phone>+ 41 22 372 93 40</phone>
      <email>alain.vonlaufen@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Philippe De Saussure, MD</last_name>
      <phone>+ 41 22 372 93 40</phone>
      <email>Philippe.DeSaussure@hcuge.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Alain Vonlaufen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>December 28, 2005</last_update_submitted>
  <last_update_submitted_qc>December 28, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2005</last_update_posted>
  <keyword>Gastrostomy</keyword>
  <keyword>Wound infection</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

